Ignite Creation Date:
2025-12-24 @ 5:53 PM
Ignite Modification Date:
2026-01-01 @ 10:27 PM
Study NCT ID:
NCT00603668
Status:
COMPLETED
Last Update Posted:
2021-08-16
First Post:
2008-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-08
Start Date Type:
None
Primary Completion Date:
2013-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-02
Completion Date Type:
ACTUAL
First Submit Date:
2008-01-08
First Submit QC Date:
None
Study First Post Date:
2008-01-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-08-16
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2021-08-12
Last Update Post Date:
2021-08-16
Last Update Post Date Type:
ACTUAL